Head to Head Comparison: Femasys (NASDAQ:FEMY) & Accuray (NASDAQ:ARAY)

Femasys (NASDAQ:FEMY) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Insider & Institutional Ownership

65.3% of Femasys shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 12.3% of Femasys shares are held by company insiders. Comparatively, 4.2% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Femasys and Accuray’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,435.77%	-141.49%	-82.30%
Accuray	-0.96%	-9.75%	-0.93%

Volatility & Risk

Femasys has a beta of -2.81, indicating that its share price is 381% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Earnings & Valuation

This table compares Femasys and Accuray”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.07 million	36.28	-$14.25 million	($0.81)	-2.09
Accuray	$446.55 million	0.50	-$15.55 million	($0.05)	-43.10

Femasys has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Femasys and Accuray, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	3	0	3.00
Accuray	0	0	0	0	0.00

Femasys currently has a consensus target price of $10.00, suggesting a potential upside of 489.97%. Given Femasys’ stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Accuray.

Summary

Femasys beats Accuray on 8 of the 14 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.